Navigation Links
Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
Date:6/30/2008

Par to Begin Shipping Dronabinol Soft Gel Capsules Immediately

WOODCLIFF LAKE, N.J., June 30 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for dronabinol, a generic version of Solvay Pharmaceutical's Marinol(R), a CIII controlled substance. This product is approved to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments and is available in 2.5mg, 5 mg and 10 mg strengths. Annual U.S. sales of Marinol are approximately $190 million, according to IMS Health data. Par will begin shipping all strengths of dronabinol soft gel capsules to the trade immediately.

Under the terms of a license and distribution agreement with SVC Pharma LP, an affiliate of Rhodes Technologies, Par has the right to market, sell and distribute dronabinol in the U.S. Par and SVC Pharma LP will share profits equally from the sales of the product.

Important information about dronabinol soft gel capsules

Dronabinol is contraindicated in any patient who has a history of hypersensitivity to any cannabinoid, sesame oil or any ingredients in dronabinol capsules. Warn patients not to drive, operate machinery, or engage in hazardous activity until they establish they can tolerate dronabinol and perform such tasks.

Dronabinol should be used with caution in patients with a history of seizure disorder; patients with cardiac disorders; patients with a history of substance abuse (including alcohol abuse or dependence); patients with mania, depression, or schizophrenia (along with careful psy
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Transfection Technology Market - Global Industry Analysis, Size, Share, ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... nucleic acids (either DNA or RNA) into cells. This ... of cancer cells and protein metabolism by affecting the ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... Pacira Pharmaceuticals, Inc., an,acute care specialty pharmaceutical company, today ... addition of a key senior,executive to the company,s management ... a seasoned biopharmaceutical executive with more than,30 years of ... Pacira as the founder and past Chairman and CEO ...
... WOODCLIFF LAKE, N.J., July 9 Par,Pharmaceutical Companies, Inc. ... shipment of 12.5mg and 25mg meclizine HCl tablets immediately. ... of the AB-rated,generic product., Par marketed meclizine prior ... in February 2008. Par has since qualified a new ...
... 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX:,LOR, ... biopharmaceutical company,specializing in the research and development ... of cancer, today announced progress made in,the ... two,research studies on the Virulizin(R) mode of ...
Cached Biology Technology:Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management 2Par Pharmaceutical to Launch meclizine HCL Tablets 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
(Date:7/10/2014)... COLORADO SPRINGS, Colo. , June 27, 2014 ... announces that the National Institute of Standards and ... appointed 10 of its academic research and forensic ... Board (FSSB).  The Board is an element of ... These AAFS members are among the first appointments ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... Ph.D., School of Biosciences, University of Birmingham, has ... his seminal work on the structural biology and ... cell walls in bacteria. Natalie Strynadka, University of ... "his spectacular abilities in structural biology clearly paved ...
... than three quarters of the volume of material destined for geological ... is to encapsulate ILW in specially formulated cement. The waste is ... disposal deep underground. Two studies, published in the latest issues ... Journal of Glass Science and Technology A show that turning ...
... Sea, a salt sea without an outlet, lies over ... salt content because it increases their buoyancy. "For ... that provides a diachronic view of its climate past," ... Geology, Mineralogy and Paleontology at the University of Bonn. ...
Cached Biology News:The American Society for Microbiology honors Andrew Lovering 2Glass offers improved means of storing UK's nuclear waste 2Drastic desertification 2Drastic desertification 3
... Biomek FXP is the latest entry in the ... positional accuracy and increased robustness, it can meet ... can be configured with either one or two ... Biomek FXP sets the standard for flexible laboratory ...
... The Biomek FX P is the ... hardware design for greater positional accuracy and increased ... about any application. It can be configured with ... large deck capacity, the Biomek FX P ...
... reduce the chance of error. Thats the ... using Beckman Coulters extensive experience in laboratory ... the CEQ 8000 is a fully automated ... the capillary array with a patented linear ...
... Detergent-OUT Kit is a simple high performance ... Removes detergents without significant dilution of ... solution on the Detergent-OUT Spin column and ... Med column is suitable for removing detergents ...
Biology Products: